SCHEMBL17547660

SCHEMBL17547660

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4cccc(Cl)c4)cc32)c(C)c1C(=O)N1CCCCC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.66
MET P08581 7/20 0.66
FGFR1 P11362 7/20 0.66
MEN1 O00255 2/20 0.66
CDK2 P24941 2/20 0.66
KMT2A Q03164 2/20 0.66
PTK2B Q14289 2/20 0.66
TDP1 Q9NUW8 2/20 0.66
CCNE1 P24864 1/20 0.66
RECQL P46063 1/20 0.66
PDGFRB P09619 6/20 0.62
EGFR P00533 3/20 0.62
SRC P12931 3/20 0.62
KIT P10721 2/20 0.62
NEK2 P51955 2/20 0.62
ALK Q9UM73 2/20 0.62
PLK4 O00444 1/20 0.62
RIOK3 O14730 1/20 0.62
CASK O14936 1/20 0.62
GAK O14976 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL145435 0.93 KDR (0.76) KDRMETFGFR1MEN1CDK2
SCHEMBL141897 0.89 MET (0.60) KDRMETFGFR1MEN1CDK2
SCHEMBL6267653 0.88 ALK (0.58) KDRMETFGFR1MEN1CDK2
SCHEMBL24974597 0.87 KDR (0.71) KDRMETFGFR1MEN1CDK2
SCHEMBL142633 0.87 KDR (0.66) KDRMETFGFR1MEN1CDK2
SCHEMBL146280 0.87 KDR (0.70) KDRMETFGFR1MEN1CDK2
SCHEMBL144136 0.86 KDR (0.59) KDRMETFGFR1MEN1CDK2
SCHEMBL141818 0.86 KDR (0.67) KDRMETFGFR1MEN1CDK2
SCHEMBL147765 0.86 KDR (0.59) KDRMETFGFR1MEN1CDK2
SCHEMBL144668 0.85 KDR (0.70) KDRMETFGFR1MEN1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160058751-A1 COMPOSITION AND METHOD FOR TREATING CANCER CELLWORKS GROUP, INC. (US) 2016-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160058751-A1 COMPOSITION AND METHOD FOR TREATING CANCER KRAS, NRAS, TP53 KDR 953/4885MET 271/4885FGFR1 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.